Ubs Group Ag F Star Therapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$2.18 - $6.39 $4,739 - $13,891	2,174 Added 4348.0%	2,224 $14,000
Q1 2022 May 16, 2022	SELL	$2.77 - $5.36 $523 - $1,013	-189 Reduced 79.08%	50 $0
Q4 2021 Feb 14, 2022	SELL	$4.71 - $7.38 $1,276 - $1,999	-271 Reduced 53.14%	239 $1,000
Q3 2021 Nov 15, 2021	SELL	$5.2 - $8.42 $2,355 - $3,814	-453 Reduced 47.04%	510 $3,000
Q2 2021 Aug 13, 2021	BUY	$6.57 - $10.71 $1,241 - $2,024	189 Added 24.42%	963 $8,000
Q1 2021 May 12, 2021	BUY	$7.09 - $13.84 $4,076 - $7,958	575 Added 288.94%	774 $9,000
Q4 2020 Feb 11, 2021	BUY	$1.03 - $10.39 $204 - $2,067	199 New	199 $1,000

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.